Other genturis

Endorsed* guidelines for other genturis

* ERN GENTURIS uses AGREE II as a tool for the endorsement of guidelines. The quality of the guideline is evaluated through assessing the rigor and transparency of the guideline development process. The content of the guideline is not evaluated.

• Von Hippel-Lindau disease: Updated guideline for diagnosis and surveillance

  Authors: Marie Louise M Binderup et al.
  European Journal of Medical Genetics. 2022 Jun 13;65(8):104538. doi: 10.1016/j.ejmg.2022.104538.

  Endorsed in June 2022

   

• A guideline for the clinical management of basal cell naevus syndrome (Gorlin–Goltz syndrome)

  Authors: Babette J.A. Verkouteren et al.
  British Journal of Dermatology (Feb 2022); 186(2): 215-226. doi: 10.1111/bjd.20700.

  Endorsed in June 2022

   

• Surveillance recommendations for DICER1 pathogenic variant carriers: a report from the SIOPE Host Genome Working Group and CanGene-CanVar Clinical Guideline Working Group

  Authors: Bakhuizen et al.
  Familial Cancer (Jun 2021); 20: 337–348. doi: 10.1007/s10689-021-00264-y.

  Endorsed in April 2021

   

• Hereditary diffuse gastric cancer: updated clinical practice guidelines
  Authors: Vanessa R Blair et al.
  Lancet Oncology (Aug 2020); 21(8): e386-e397. doi: 10.1016/S1470-2045(20)30219-9.

  Endorsed in October 2020

   

• Small-Cell Carcinoma of the Ovary, Hypercalcemic Type – Genetics, New Treatment Targets, and Current Management Guidelines
  Authors: Marc Tischkowitz et al.
  Clinical Cancer Research (Aug 2020); 26(15): 3908–3917. Published Online on March 10, 2020; doi: 10.1158/1078-0432.CCR-19-3797

  Endorsed in March 2020